Immune Therapeutics Retains Investor Relations Partners to Support Company’s Strategic IR Program as it Prepares for Commercialziation

ORLANDO, Fla., Jan. 26, 2017 -- Investor Relations Partners (IRP), one of the fastest growing investor and public relations firms in the nation, today announced that Immune Therapeutics Inc. (OTCQB:IMUN), a clinical-stage company developing novel therapies for the treatment of immuno-inflammatory diseases and cancer, has retained IRP to expand the Company’s strategic investor relations program.

“Immune Therapeutics achieved a number of milestones in 2016 that set the groundwork for what should be the single most important year for the Company since its inception,” said Noreen Griffith, Chief Executive Officer of Immune Therapeutics, Inc. “This year’s goals will include reaching a number of significant milestones for the Company, including but not limited to, launching into full commercialization, growing revenues at a rate fast enough to enable us to achieve profitability and of course expanding our product lines both within existing and new customers.  We have retained IRP to help communicate the series of expected positive developments to the investment community in an effort to significantly increase our exposure as well as support our overriding goal of building shareholder value,” concluded Ms. Griffith.

To be added to the Company’s investor lists, please contact Kevin Yamano at Investor Relations Partners at 818-280-6800 or via email at [email protected]. 

About Investor Relations Partners

Investor Relations Partners, Inc. (IRP) is a full-service investor relations firm serving a global client base.  The principals of IRP have received top industry awards for their investor relations programs for a number of high-profile companies, including, but not limited to, Starwood Hotels & Resorts Worldwide, ValueVision Media, Taro Pharmaceuticals, and LJ International. The firm’s principals have executed effective investor relations programs for dozens of public companies, ranging from emerging micro-cap companies to multinational corporations with market capitalizations in excess of $15 billion.  For further information on IRP, please visit the firm’s Website at www.irpartnersinc.com.

About Immune Therapeutics:

Immune Therapeutics is a biotechnology company working to combat chronic, life-threatening diseases through the activation and modulation of the body's immune system using its patented immunotherapies with a focus of providing such therapies in emerging nations. Its products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory and autoimmune diseases.

Immune Therapeutics' proprietary technology, therapies and patents include the treatment of a wide range of cancers. Its most advanced clinical programs involve immunotherapy with met-enkephalin (MENK) (sometimes referred to as opioid growth factor) and its Low Dose Naltrexone product (LDN) or Lodonal™, which have been shown to stimulate the immune system even in patients with advanced cancer.

Forward Looking Statements
This release may contain forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to, the possibility that some or all of the matters and transactions considered by the Company may not proceed as contemplated, and by all other matters specified in the Company's filings with the Securities and Exchange Commission. These statements are made based upon current expectations that are subject to risk and uncertainty. The Company does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in the Company's filings with the Securities and Exchange Commission (www.sec.gov), including its recent periodic reports. 

Investor/Media Contact:				
Kevin Yamano
Investor Relations Partners
Phone: 818-280-6800
[email protected]